Literature DB >> 27105448

Carnosine and Homocarnosine Degradation Mechanisms by the Human Carnosinase Enzyme CN1: Insights from Multiscale Simulations.

Matic Pavlin1,2, Giulia Rossetti2,3,4, Marco De Vivo2,5, Paolo Carloni1,2.   

Abstract

The endogenous dipeptide l-carnosine, and its derivative homocarnosine, prevent and reduce several pathologies like amytrophic lateral sclerosis (ALS), Alzheimer's disease, and Parkinson's disease. Their beneficial action is severely hampered because of the hydrolysis by carnosinase enzymes, in particular the human carnosinase, hCN1. This belongs to the metallopeptidase M20 family, where a cocatalytic active site is formed by two Zn(2+) ions, bridged by a hydroxide anion. The protein may exist as a monomer and as a dimer in vivo. Here we used hybrid quantum mechanics/molecular mechanics simulations based on the dimeric apoenzyme's structural information to predict the Michaelis complexes with l-carnosine and its derivative homocarnosine. On the basis of our calculations, we suggest that (i) l-carnosine degradation occurs through a nucleophilic attack of a Zn(2+)-coordinated bridging moiety for both monomer and dimer. This mechanistic hypothesis for hCN1 catalysis differs from previous proposals, while it is in agreement with available experimental data. (ii) The experimentally measured higher affinity of homocarnosine for the enzyme relative to l-carnosine might be explained, at least in part, by more extensive interactions inside the monomeric and dimeric hCN1's active site. (iii) Hydrogen bonds at the binding site, present in the dimer but absent in the monomer, might play a role in the experimentally observed higher activity of the dimeric form. Investigations of the enzymatic reaction are required to establish or disprove this hypothesis. Our results may serve as a basis for the design of potent hCN1 inhibitors.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27105448     DOI: 10.1021/acs.biochem.5b01263

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  5 in total

1.  A multiscale approach to predict the binding mode of metallo beta-lactamase inhibitors.

Authors:  Silvia Gervasoni; James Spencer; Philip Hinchliffe; Alessandro Pedretti; Franco Vairoletti; Graciela Mahler; Adrian J Mulholland
Journal:  Proteins       Date:  2021-09-20

Review 2.  Carnosinase, diabetes mellitus and the potential relevance of carnosinase deficiency.

Authors:  Verena Peters; Johannes Zschocke; Claus P Schmitt
Journal:  J Inherit Metab Dis       Date:  2017-10-13       Impact factor: 4.982

3.  Allosteric inhibition of carnosinase (CN1) by inducing a conformational shift.

Authors:  Verena Peters; Claus P Schmitt; Tim Weigand; Kristina Klingbeil; Christian Thiel; Antje van den Berg; Vittorio Calabrese; Peter Nawroth; Thomas Fleming; Elisabete Forsberg; Andreas H Wagner; Markus Hecker; Giulio Vistoli
Journal:  J Enzyme Inhib Med Chem       Date:  2017-12       Impact factor: 5.051

4.  Responsiveness of Carnosine Homeostasis Genes in the Pancreas and Brain of Streptozotocin-Treated Mice Exposed to Dietary Carnosine.

Authors:  Amilcare Barca; Francesca Gatti; Daniela Spagnolo; Stefania Ippati; Carla Vetrugno; Tiziano Verri
Journal:  Int J Mol Sci       Date:  2018-06-09       Impact factor: 5.923

Review 5.  Carnosine, Small but Mighty-Prospect of Use as Functional Ingredient for Functional Food Formulation.

Authors:  Ivana Jukić; Nikolina Kolobarić; Ana Stupin; Anita Matić; Nataša Kozina; Zrinka Mihaljević; Martina Mihalj; Petar Šušnjara; Marko Stupin; Željka Breškić Ćurić; Kristina Selthofer-Relatić; Aleksandar Kibel; Anamarija Lukinac; Luka Kolar; Gordana Kralik; Zlata Kralik; Aleksandar Széchenyi; Marija Jozanović; Olivera Galović; Martina Medvidović-Kosanović; Ines Drenjančević
Journal:  Antioxidants (Basel)       Date:  2021-06-28
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.